H.R. 8630

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 8630 Introduced in House (IH)]

<DOC>

119th CONGRESS
2d Session
H. R. 8630

To amend the Public Health Service Act to prohibit treatment of a 
biologic as a biological product based solely on the presence of a 
protein that is a clinically inactive component in such biologic, and 
for other purposes.

_______________________________________________________________________

IN THE HOUSE OF REPRESENTATIVES

April 30, 2026

Mr. Rulli (for himself and Mrs. Harshbarger) introduced the following 
bill; which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

A BILL

To amend the Public Health Service Act to prohibit treatment of a 
biologic as a biological product based solely on the presence of a 
protein that is a clinically inactive component in such biologic, and 
for other purposes.

Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the ``Protecting Equal Access to Thyroid 
Act of 2026'' or the ``PEAT Act of 2026''.

SEC. 2. PROHIBITION WITH RESPECT TO TREATMENT OF PROTEINS IN BIOLOGICS.

(a) In General.--Section 351(i)(1) of the Public Health Service Act 
(42 U.S.C. 262(i)(1)) is amended--
(1) by striking ``The term'' and inserting the following:
``(A) The term''; and
(2) by adding at the end the following:
``(B) A biologic described in subparagraph (A) may 
not be treated as a biological product based solely on 
the presence of a protein that is a clinically inactive 
component in such biologic.''.
(b) Technical Correction.--Section 351(i)(1) of the Public Health 
Service Act (42 U.S.C. 262(i)(1)) is amended in subparagraph (A), as 
designated by subsection (a)(1), by striking ``protein ,'' and 
inserting ``protein,''.
<all>